by MM360 Staff | Sep 7, 2025 | Uncategorized
Source: CureToday articles Data from the AQUILA study support the use of fixed-duration subcutaneous Darzalex Faspro as an early treatment option in high-risk smoldering myeloma. Read More
by MM360 Staff | Aug 23, 2025 | Uncategorized
Source: CureToday articles Multiple myeloma is a chronic blood cancer affecting plasma cells, but with today’s treatments many patients can manage symptoms and live fulfilling lives. Read More
by MM360 Staff | Aug 21, 2025 | Uncategorized
Source: CureToday articles The FDA declined approval of Darzalex Faspro for newly diagnosed, transplant-ineligible multiple myeloma in its current form. Read More
by MM360 Staff | Aug 15, 2025 | Uncategorized
Source: CureToday articles Dr. Jim Omel, who was diagnosed with multiple myeloma in 1997, explained how the treatment landscape has changed over nearly 30 years. Read More
by MM360 Staff | Aug 13, 2025 | Uncategorized
Source: CureToday articles Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T cell engagers, along with potent new CELMoD drugs, all offering more targeted and effective options for patients. Read...
by MM360 Staff | Aug 12, 2025 | Uncategorized
Source: CureToday articles Ashley Dieks and Dr. Saad Z. Usmani discussed how bicycling may help patients cope with the emotional and physical challenges of their myeloma diagnosis. Read More
